CATALOGO DEI PRODOTTI DELLA RICERCA

CINGARLINI, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.448
EU - Europa 3.021
AS - Asia 2.163
SA - Sud America 304
AF - Africa 39
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.390
CN - Cina 956
GB - Regno Unito 945
SG - Singapore 706
IT - Italia 445
SE - Svezia 317
DE - Germania 296
BR - Brasile 268
IE - Irlanda 263
HK - Hong Kong 244
FR - Francia 210
RU - Federazione Russa 198
FI - Finlandia 164
KR - Corea 47
VN - Vietnam 42
TR - Turchia 38
NL - Olanda 36
UA - Ucraina 35
BE - Belgio 29
JP - Giappone 29
CA - Canada 26
IN - India 25
MX - Messico 20
ES - Italia 19
AT - Austria 15
IR - Iran 15
ZA - Sudafrica 11
IQ - Iraq 9
AR - Argentina 8
BD - Bangladesh 8
ID - Indonesia 8
LV - Lettonia 8
PL - Polonia 8
AU - Australia 6
AZ - Azerbaigian 6
CH - Svizzera 6
CL - Cile 6
MA - Marocco 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
PE - Perù 5
PH - Filippine 5
JM - Giamaica 4
TG - Togo 4
UY - Uruguay 4
UZ - Uzbekistan 4
CO - Colombia 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
EC - Ecuador 3
IL - Israele 3
KE - Kenya 3
MK - Macedonia 3
AL - Albania 2
CM - Camerun 2
DK - Danimarca 2
ET - Etiopia 2
HR - Croazia 2
KZ - Kazakistan 2
LT - Lituania 2
NO - Norvegia 2
PA - Panama 2
RO - Romania 2
SA - Arabia Saudita 2
SI - Slovenia 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IM - Isola di Man 1
JO - Giordania 1
ME - Montenegro 1
MQ - Martinica 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
PW - Palau 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 8.985
Salva come PNG Salva come JPEG
Città #
Southend 866
Chandler 614
Dallas 504
Singapore 334
Dublin 254
Jacksonville 245
Hong Kong 238
Ann Arbor 214
Ashburn 209
Woodbridge 204
Beijing 183
Verona 140
New York 99
Houston 86
Munich 82
Jinan 76
Lawrence 76
Princeton 76
Wilmington 72
Shenyang 70
Helsinki 60
Nanjing 53
The Dalles 51
Tianjin 41
Hebei 40
São Paulo 35
Columbus 34
Haikou 34
Changsha 33
Milan 33
Los Angeles 32
Redmond 32
Zhengzhou 31
Guangzhou 30
Brussels 29
Bologna 24
Seattle 24
Sindelfingen 24
Nanchang 23
Taiyuan 23
Tokyo 23
Hangzhou 22
Turku 21
Ningbo 20
Santa Clara 20
Taizhou 20
Lancaster 19
Redwood City 19
Seoul 18
San Francisco 16
Jiaxing 15
Kent 13
Boardman 12
Council Bluffs 12
Dong Ket 12
Washington 11
Buffalo 10
Frankfurt am Main 10
Fuzhou 10
Amsterdam 9
Brescia 9
Mexico City 9
Norwalk 9
Nuremberg 9
Shanghai 9
Toronto 9
Belo Horizonte 8
Chennai 8
Chicago 8
Dearborn 8
Ho Chi Minh City 8
Johannesburg 8
Moscow 8
Rio de Janeiro 8
Rome 8
Falkenstein 7
Baku 6
Curitiba 6
Desenzano del Garda 6
Düsseldorf 6
Genova 6
Jakarta 6
Lappeenranta 6
Leawood 6
London 6
Stockholm 6
Warsaw 6
Brooklyn 5
Denver 5
Dongguan 5
Florence 5
Foresto 5
Hamburg 5
Kyoto 5
Montreal 5
Salvador 5
Vienna 5
Atlanta 4
Baghdad 4
Cagliari 4
Totale 5.901
Salva come PNG Salva come JPEG
Nome #
Whole-genome landscape of pancreatic neuroendocrine tumours 204
Anti PSMA immunotoxins activity against prostate cancer cell lines. 194
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 167
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 164
The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. 157
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 152
Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results from a Single-Center Surgical Series 152
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 151
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 149
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 146
Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors 145
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 145
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 144
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 141
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 139
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 138
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 135
CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms 135
Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components 133
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 132
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 132
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 131
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 130
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 130
3D-CT texture analysis of neuroendocrine pancreatic neoplasms 130
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 129
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 129
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 129
A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy 128
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 127
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 123
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 123
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 121
Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and 18F-FDG Uptake 119
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 119
Pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies: a case report and review of the literature 118
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 117
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 117
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 114
ESGAR 2016 Book of Abstracts 114
The development of PARP as a successful target for cancer therapy 113
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 110
Imaging presentation of pancreatic neuroendocrine neoplasms 109
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 108
Dual-tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 non-functioning pancreatic neuroendocrine tumors: A single-center retrospective evaluation of 124 non-metastatic resected cases 108
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 107
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 107
Preclinical studies of a new anti-psma (prostate specific membrane antigen) antibody for diagnosis and immunotargeting 106
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 104
Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience 102
Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases 101
Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? 99
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 98
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 98
Solid non-functioning endocrine tumors of the pancreas: correlating computed tomography and pathology 98
Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms 97
Prognostic Stratification and Therapeutic Response Assessment in Liver and Pancreatic Tumors: the New Imaging 96
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 96
Profiling mTOR pathway in neuroendocrine tumors 95
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 95
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 94
Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors 94
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 92
Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors: Why Not? 92
Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome 90
Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging 87
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 86
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 85
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 82
Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms 79
Differentiation of pancreatic neuroendocrine tumor grade comparing 3D CT texture analysis and relative CT enhancement ratios 77
Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study 75
Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum? 74
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 71
Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring 71
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size 68
Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center 52
Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors 50
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 47
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? 47
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 42
Somatostatin analogs for resectable pancreatic neuroendocrine tumors in high-risk surgical patients: Data from a single-center cohort 25
Totale 9.130
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.266
article - articoli 23.239
book - libri 0
conference - conferenze 9.566
curatela - curatele 0
other - altro 398
patent - brevetti 738
selected - selezionate 0
volume - volumi 325
Totale 68.532
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021464 0 0 44 89 82 50 14 37 41 17 62 28
2021/2022786 65 256 18 70 37 17 14 44 23 18 53 171
2022/20231.625 96 211 148 287 108 429 38 88 173 9 25 13
2023/2024835 29 66 75 82 90 166 25 50 9 65 144 34
2024/20251.933 104 112 108 273 99 76 104 88 279 137 182 371
2025/20261.114 412 354 348 0 0 0 0 0 0 0 0 0
Totale 9.130